Replies to post #41484 on Cytogenix (fka CYGX)

[Tatonkano62]

Stockguru.com: CPC of America's Subsidiary Produces Successful Prelimiary Results While Other Companies Prepare for Conferences, Receive Notices, Conduct Meetings with the FDA and Update Data

TUESDAY , OCTOBER 31, 2006 08:43 AM

Dallas, Texas, Oct 31, 2006 (M2 PRESSWIRE via COMTEX) -- StockGuru Pre-Market Updates for Tuesday include Northwest Biotherapeutics, Inc. (OTCBB NWBT), Advaxis, Inc. (OTCBB ADXS), Viral Genetics, Inc. (OTCBB VRAL), CPC of America, Inc. (OTCBB CPCF), CytoGenix, Inc. (OTCBB CYGX), and Chembio Diagnostics, Inc. (OTCBB CEMI).

StockGuru Alerts feature companies with significant corporate news within the last ten days. In our update we analyze information about the companies featured and detail the movement in the stock.

If you would like to feature your publicly traded company in our alerts or on StockGuru.com, email [e-mail] or call [phone].

Chembio Diagnostics, Inc. (OTCBB CEMI) Monday's market went up 5.13% to $0.82 per share, with a total of 99,400 shares traded. The company issued the following updates and finalized list of presenters for Paulson Investment's 29th Annual Westergaard SmallCap Conference. The Conference will showcase small and emerging growth companies focused on establishing leadership in a broad range of industry sectors, including alternative energy, security, technology, pharmaceutical, biotechnology, environmental and consumer products. Founded in 1978 by noted small cap analyst John Westergaard, this conference provides a venue for select small cap companies to share detailed insight into their business operations, short and long term growth strategies, and industry vision.

Chembio Diagnostics, Inc. and its subsidiaries engage in the development, manufacture, and marketing of lateral flow rapid diagnostic tests for detecting infectious diseases in the United States and internationally. The company primarily offers SURE CHECK HIV, HIV 1/2 STAT-PAK, and HIV 1/2 STAT-PAK Dipstick rapid tests for use in the diagnosis of infectious diseases and other conditions in humans and animals, as well as for Chagas disease and Lyme disease. It is also developing rapid tests for other infectious diseases, such as rapid tests for human and veterinary tuberculosis. Chembio Diagnostics sells its tests to medical laboratories and hospitals, governmental and public health entities, nongovernmental organizations, medical professionals, and retail establishments in Africa, South America, and Asia. The company was founded in 1985 and is based in Medford, New York.

For a quote and the latest news on this company, please visit: http://www.stockguru.com/profiles/CEMI.php .

CytoGenix, Inc. (OTCBB CYGX) Monday's market stayed the same at $ 0.75 per share, with a total of 94,069 shares traded. The company has received notices of allowances for grant of patent applications covering the technology for expressing ssDNA In Vivo, from the Indian and European Community Patent Offices. These notices follow the previous notice of allowance for these applications from the Peoples Republic of China. Filed in 1999 and 2000, these patents cover the company's single-strand DNA expression system covered by a US patent and by several patent applications in major world markets. Used in the company's Simplivir(TM) anti-herpes and CY303 anti inflammation products, an ssDNA gene silencing compound is active in reducing tumors in a melanoma experimental animal model. Dr. Yin Chen, CytoGenix, Inc. Vice President, Chief Scientific Officer and a co-inventor of the single-strand DNA expression technology, states, "This is another step in our intellectual property strategy for this technology. These countries offer significant market opportunities and we are seeking appropriate licensees and partners."

CytoGenix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of its technology for identifying and silencing disease causing genes and expressing proteins for applications, such as vaccines. The company's technology includes gene silencing techniques applicable to genes from pathogenic organisms or selected genes from a host to prevent the expression of harmful proteins, thereby preventing, or ameliorating disease. It also develops a process to produce cell free, plasmid DNA for sale to the biopharmaceutical market. The company's products under development include CY301 for prophylactic and neonatal applications; CY401, which targets multidrug resistant bacteria, including methicillin-resistant staphylococcus aureus; CY403, which targets the staphylococcus species; and CY303, an anti-inflammatory product. It has a research agreement with the University of Texas for preclinical animal studies of synDNA H5N1 vaccine. The company was founded as Cryogenic Solutions, Inc. in 1995 and changed its name to CytoGenix, Inc. in 2000. CytoGenix is based in Houston, Texas.

For a quote and the latest news on this company, please visit: http://www.stockguru.com/profiles/CYGX.php .

CPC of America, Inc. (OTCBB CPCF) Monday's market went up 6.06% to $21.00 per share, with a total of 84,909 shares traded. The company reports that it's subsidiary, Med Enclosure, LLC, in its very preliminary findings of the "Randomized, Prospective, Multi-Center Trial of the MedClose(TM) VCS" produced successful results with no adverse affects reported in diagnostic and interventional studies. The "Randomized, Prospective, Multi-Center Trial of the MedClose(TM) VCS" as a "non significant/low risk" device determined by both a US Independent Review Board and a Canadian Independent Review Board with subsequent approval by the Canadian Health, Health Products and Food Branch, Therapeutic Products Division for Protocol #CL-7000 is intended to seal femoral arterial puncture sites and reduce time to hemostasis and ambulation in patients who have undergone interventional and diagnostic catheterization procedures. The "non significant/low risk" determination recognizes that the MedClose(TM) plug-mediated Vascular Closure Device ("VCD") as an alternative to manual compression does not present a "significant risk" per 21CFR 821.3(l)(m), and the MedClose(TM) VCS and the FDA licensed biologic (fibrin plug) does not meet the definition of an "implant." The fibrin plug is resorbed within "10-14" days. The MedClose(TM) and the delivered fibrin plug are not intended for use in supporting or saving lives, or for the purpose of diagnosing, curing, mitigating, or treating disease, or preventing impairment of human health. The FDA licensed biologic (fibrin plug) does not present a potential for serious risk to health, safety, or welfare of a subject. The Company upon completion of its "Randomized, Prospective, Multi-Center Trial of the MedClose(TM) VCS" expects to submit applications for both the CE Mark and Pre Market ("PMA") by Q2/2007.

CPC of America, Inc., a development stage company, engages in the development and acquisition of cardiology medical devices, therapeutic devices, and disposable products. It also involves in the manufacture and distribution of these devices and products for the diagnosis and treatment of coronary artery disease. The company's principal product, CPCA 2000, is used as an external counterpulsation device for the treatment of coronary artery disease. It is also developing MedClose, an internal puncture closure device and technique that utilizes a human glue deployment to close puncture wounds following surgery. The company was formed in 1996 and is based in Sarasota, Florida.

For a quote and the latest news on this company, please visit: http://www.stockguru.com/profiles/CPCF.php .

Viral Genetics, Inc. (OTCBB VRAL) Monday's market went down 4.46% to $0.105 per share, with a total of 108,300 shares traded. The company recent AIDS study of VGV-1 in South Africa will be presented at the Institute of Human Virology's (IHV) 2006 Annual International Meeting on November 17 in Baltimore, Maryland. The poster presentation focuses on the reduction of HIV viral load observed in a subset of patients after treatment with VGV-1 versus patients receiving placebo. Viral Genetics' VGV-1 is a suspension of thymus nuclear protein that has been tested in several studies in HIV infected individuals. As previously reported, the 137-patient study showed statistically significant antiviral effects in treated subjects vs. placebo 100 days after the completion of dosing. As reported in the Company's poster presentation at the recent XVI International AIDS Conference, VGV-1 treated subjects also demonstrated apparent beneficial immunological changes when compared with placebo.

Viral Genetics, Inc., a development stage company, engages in the research and development of protein-based therapeutic and diagnostic products in the United States. The company develops its products based on thymus nuclear protein compound, a processed extract of mammalian thymus tissue. Its products are used in infectious disease, autoimmune conditions, and immunological deficiency applications. The company's drug candidate VGV-1, a suspension of thymus nuclear protein in adjuvant, is used for the treatment of HIV and AIDS. The product had completed five human clinical trials in South Africa, China, Bulgaria, and Mexico, and is in the preclinical stage of development in the United States. Viral Genetics was founded in 1995 and is based in Azusa, California.

For a quote and the latest news on this company, please visit: http://www.stockguru.com/profiles/VRAL.php .

Advaxis, Inc. (OTCBB ADXS) Monday's market went down 2.50% to $0.1950 per share, with a total of 199,300 shares traded. The company has conducted a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its two planned Phase II studies for its lead product Lovaxin C, a live Listeria vaccine for the treatment of cervical as well as head and neck cancers. The FDA has reviewed information provided by the Company on its methods, procedures and results to date, and provided guidance for the submission of an investigational new drug (IND) application and future product development. The Company has proposed Phase II trials in cervical and head and neck cancers that are each expected to consist of 60 early stage cancer patients. The objectives of these trials are to assess the regimens for the safety and efficacy of Lovaxin C. In both trials the Company will measure time to progression and survival endpoints, immuno-genetic ability, and safety parameters. Pre-clinical data for Lovaxin C has shown an extremely efficacious immune response to tumors upon administration of the drug with an overall response rate of 100% and complete eradication of tumors in more than half of the animals tested. "We are working closely with the FDA to ensure all requirements are met as we prepare to progress through our clinical studies and are quite pleased with the progress we have made," said Dr. John Rothman, VP Clinical Development. "We look forward to advancing Lovaxin C as well as our other cancer vaccines through the clinical trials."

Advaxis, Inc., a development stage biotechnology company, engages in the research and development of cancer vaccines. It focuses on developing cancer vaccines targeting cervical, breast, prostate, ovarian, lung, and other cancers. The company uses its licensed Listeria System to engineer live attenuated Listeria monocytogenes bacteria to secrete protein sequence containing a tumor-specific antigen, force the body's immune system to process and recognize the antigen, and create the immune response needed to attack the cancer. Its lead products in pre clinical stage include Lovaxin C for cervical and head and neck cancers; Lovaxin B for breast cancer and melanoma; Lovaxin P for prostate cancer; Lovaxin W for Wilms tumor and leukemia; Lovaxin T for cancer through control of telomerase; Lovaxin H for prophylactic vaccine for HIV; Lovaxin SCCE to treat ovarian and pancreatic cancer based upon the antigen stratum corneum chymotryptic enzyme; Lovaxin NY for ovarian melanoma and lung cancer; and Lovaxin G, a high molecular weight melanoma associated antigen to treat central nervous system cancer. The company has strategic collaboration with Cobra Biomanufacturing PLC for the purpose of manufacturing cervical cancer vaccine; and with Pharm-Olam International, Ltd. to execute and manage its Phase 1 clinical trial in Lovaxin C. Advaxis was founded in 2002 and is headquartered in North Brunswick, New Jersey.

For a quote and the latest news on this company, please visit: http://www.stockguru.com/profiles/ADXS.php .

Northwest Biotherapeutics, Inc. (OTCBB NWBT) Monday's market went up 5.00% to $0.105 per share, with a total of 319,000 shares traded. The company updated survival and progression data on patients from two clinical trials carried out at The University of California at Los Angeles (UCLA). The patients were treated with DCVax -Brain, a personalized cancer immunotherapy, for Glioblastoma multiforme (GBM). The report was given today at 8:30 a.m. at the C.E. Unterberg, Towbin Life Sciences Conference today in New York City, and at the Annual Meeting of the International Society of Biological Therapy for Cancer held in Los Angeles on October 26-28. A landmark analysis of disease progression at two years showed that 44% of DCVax -Brain treated GBM patients were progression-free (with no return of their cancer), while only 11% of historical control patients were progression-free at two years (n=278, Stupp et. al., N. Eng. J. Med., 352: 987, 2005): a 4-fold improvement (p<0.005). Overall survival at two years also showed a significant treatment effect: 68% of DCVax -Brain treated patients were still alive, compared with only 26% of historical control patients: a 2.6-fold improvement (p<0.001).

Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in the discovery, development, and commercialization of immunotherapy products to treat cancer. It has two platform technologies, dendritic cell-based cancer vaccines and monoclonal antibodies for cancer therapeutics. The company's primary products include DCVax-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent nonmetastatic prostate cancer, which is entering Phase III clinical trial; DCVax-Brain, a personalized dendritic cell vaccine, which is entering Phase II clinical trials, for treatment of Glioblastoma multiforme. Northwest Biotherapeutics also develops monoclonal antibodies to CXCR4, what are in late preclinical development stages for the treatment of cancers, including breast cancer, glioblastoma, colon cancer, and melanoma. In addition, it develops DCVax-Lung, a Phase I clinical trial product for the treatment of nonsmall cell lung cancer; and DCVax-Direct, which is under preclinical stages for the treatment of head and neck cancer, nonsmall cell lung, and brain cancers. The company was founded in 1996 and is headquartered in Bothell, Washington.

For a quote and the latest news on this company, please visit: http://www.stockguru.com/profiles/NWBT.php .

About StockGuru.com:

StockGuru.com features daily alerts going out three times daily to members. To join our email alert list, please visit: http://www.stockguru.com/stocks.htm .

To feature your publicly traded company in our alerts, or to discuss our complete services, please contact: John Pentony at [phone]. Our services include our StockGuru Pre-Market Alerts, StockGuru Volume Alerts, StockGuru Price Alerts, StockGuru Midday Alerts, and StockGuru After The Bell. Additionally we Profile publicly traded companies on our web site, we do interviews with CEO's or other key executives on our web site, and we have our financial writers cover our companies.

Those interested may also email: [e-mail] or call [phone] and we will gladly send more information on featuring your company with StockGuru.com.

Stockguru.com ("SG") provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements.

CONTACT: John Pentony, Publisher Tel: [phone] e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2006 M2 COMMUNICATIONS LTD

[Tatonkano62]

We are getting our facility.....if it doesn't make us go broke



On October 30, 2006, CytoGenix, Inc. (the “Company”) entered into an Ernest Money Contract of Design/Build Project (the “Construction Agreement”) with GSL Constructors, Ltd. (“GSL”). The Construction Agreement contemplates the design, construction and purchase by the Company of an approximately 20,000 square foot, single story office building and synthetic DNA production laboratory (the “Facility”) on approximately 2.274 acres in Harris County, Texas (the “Site”). The total purchase price for the Facility and Site is $3,796,577, and the Company paid $474,571.50 to an escrow agent on October 30, 2006. A payment of $474,571.50 becomes due and payable to GSL upon commencement of construction of the interior of the Facility and the balance ($2,847,433) becomes due and payable to GSL upon completion of construction. The Company does not presently possess working capital sufficient to pay the foregoing purchase price installments, and the Company will be required to obtain financing in order to do so. There can be no assurance that the necessary financing will be available to fund the payment of the purchase price installments when they become due or, if available, that such financing will be on terms satisfactory or favorable to the Company.

The Company may cancel the Construction Agreement during the 10-day period following its receipt of a phase one environmental site assessment if that assessment determines there is environmental contamination at the Site or recommends phase II testing. The Company has other limited cancellation rights during the 21-day period following October 30, 2006 but may be required to pay up to $25,000 to GSL upon cancellation.

A copy of the Construction Agreement is attached to this Form 8-K as Exhibit 10.1. The Construction Agreement is incorporated herein in its entirety by reference in response to this Item. The foregoing description of the terms and provisions thereof is a summary only, and is qualified in its entirety by reference to such documents. On November 3, 2006, the Company issued a press release a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS.

(c)

Exhibits.

10.1.

Ernest Money Contract of Design/Build Project dated October 30, 2006 between CytoGenix, Inc. and GSL Constructors, Ltd.

99.1.

Press Release dated November 3, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2006


CytoGenix, Inc.


By /s/ Lawrence Wunderlich

Lawrence Wunderlich, Chief Financial Officer